Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive regulatory T cells (Tregs). However, off-target immune cell activation and short serum half-life limit the clinical potential of IL-2...

Full description

Bibliographic Details
Main Authors:	VanDyke, D, Iglesias, M, Tomala, J, Young, A, Smith, J, Perry, JA, Gebara, E, Cross, AR, Cheung, LS, Dykema, AG, Orcutt-Jahns, BT, Henclová, T, Golias, J, Balolong, J, Tomasovic, LM, Funda, D, Meyer, AS, Pardoll, DM, Hester, J, Issa, F, Hunter, CA, Anderson, MS, Bluestone, JA, Raimondi, G, Spangler, JB
Format:	Journal article
Language:	English
Published:	Cell Press 2022

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Similar Items